Mission BioCapital

We’re pleased to share that we’ve secured $28.4 million in an oversubscribed Series A financing round, co-led by Mission BioCapital and 4BIO Capital. This milestone brings our total funding to over $51 million and will help us accelerate the Phase 2 development of MB-105, our lead CAR-T therapy candidate for T-cell lymphoma – a type of cancer with a poor prognosis and limited treatment options.   Launching our Series A with a Phase 2 ready asset is something we're proud of and we are determined to push forward to provide new hope for patients with cancer who have few treatment options. We’re grateful to our new and existing investors for their confidence in our mission to transform the treatment landscape for challenging cancers!   https://lnkd.in/gySMtkWc #CellTherapy #Oncology #CancerResearch #SeriesA #CART #BiotechInnovation KdT Ventures TMC Venture Fund Portal Innovations, LLC Cancer Focus Fund Small Ventures USA LLC Alexandria Real Estate Equities, Inc. Modi Ventures Joe Mansueto Nancy Chang Stefan Wildt Cassidy Blundell Owen Smith Cancer Prevention and Research Institute of Texas

We are thrilled to announce that the official Grand Opening Celebration of BioLabs New Haven is just around the corner—less than three weeks away! 🗓️ Wednesday, September 25th. Join us as we welcome you into our new space at 101 College Street in New Haven. It’s going to be a fantastic event with special remarks from Mayor Justin Elicker and BioLabs CEO Johannes Fruehauf. We would love for you to be part of this milestone moment. Don’t miss out on celebrating with us and connecting with New Haven's vibrant life science community. #GrandOpening #NewHaven #Networking #Innovation #LifeScience #Biotech #Community https://lu.ma/pvwrksew

Thank you Johnson & Johnson Innovation and Mission BioCapital for cohosting a lovely VC University Life Science Scholars dinner with us in Boston this week! We convened an impressive group of alumni to network with and learn from VC leaders about building a VC career.

Our network is growing: The University of Vermont (UVM) is partnering with BioLabs to open a new incubator in early 2025 - the BioLabs Innovation Center at UVM. Together we will support founders and early-stage life sciences startups, providing state-of-the-art equipped office and lab spaces. Startups will benefit from access to UVM's research, faculty collaboration, and BioLabs' industry connections. Learn more about our new cooperation: https://lnkd.in/e_BikgEF Stay tuned as we will open applications for startups and tours in the coming months and we are excited to see innovations and breakthroughs. Johannes Fruehauf, Kirk Dombrowski, Corine Farewell image credit: University of Vermont / Sally McCay

We are really excited about our new partnership with BioLabs. Work is underway to open a facility that will really move the needle on our innovation ecosystem and activate the economic potential of #UVMResearch. Special thanks to Johannes Fruehauf and Susan Chase from the Biolabs Team, and Kate Tracy and the The Robert Larner, M.D. College of Medicine at The University of Vermont for their partnership. https://lnkd.in/erJuXj6C

We’re pleased to introduce the newest VC University scholarship recipients! The Cohort 17 scholarship class is incredibly diverse across geography, gender, ethnicity, and more: 💥 88% identify as people of color 💥 60% identify as women or nonbinary 💥 50% live outside CA, MA, and NY (the 3 states with the majority of VC activity) 💥 30% identify as LGBTQ+ 💥 5% are veterans or active military members Many thanks to our program sponsors Foresite Capital, Johnson & Johnson Innovation - JJDC, Longitude Capital, Mission BioCapital, Omega Funds, Salesforce Ventures, GV (Google Ventures), and Sofinnova Investments , whose support covers the recipients’ tuition and provides access to dedicated resources, office hours, and mentorship. Get to know the C17 scholarship class: https://lnkd.in/dQ-cDibM

🚀 D-2: The European Platinum Ticket – Your Launchpad for Biotech Innovation 🧬 Only two days left to apply for the prestigious European Platinum Ticket program, brought to you by Mission BioCapital, BioLabs, and Eli Lilly and Company. This program offers early-stage life science startups critical funding, lab space at BioLabs, and invaluable mentoring. Don't just take our word for it - hear from Bastian Linder, CSO of Umlaut.bio GmbH, one of our recent winners: “Winning the Platinum Ticket was a significant validation for our team. It propelled us forward, providing the resources to advance from incorporation to intensifying our R&D at BioLabs Heidelberg. Without the Ticket, we might still be confined to a research institute. At BioLabs, we benefit from extensive instruments, a robust network, and numerous partnering opportunities. I highly recommend early-stage startups apply for the European Platinum Ticket – it can be your launchpad. You'll gain crucial feedback and essential support for your innovation and next steps.” Don't miss this opportunity to elevate your startup. Apply now and become part of our dynamic community of biotech pioneers! Apply online until August 2, 2024: https://lnkd.in/eQHMcdaC BioLabs France, BioLabs Heidelberg, Ann-Kristin Mueller, Christophe Tallec, Hélène Sire, Johanna Michielin, Johannes Fruehauf, Jennifer Griffin Let's spread the word on this great chance for European Startups: Life Science Accelerator Baden-Württemberg, German Accelerator, Heidelberg Biotech Simulator, BioRN Life Science Cluster Rhine-Neckar, Nucleate Germany, EMBL, 5-HT Chemistry & Health , EIT Health, HTGF | High-Tech Gründerfonds, CUBEX 41 & CUBEX ONE, H3 Health Hub, Berlin Partner für Wirtschaft und Technologie GmbH, Life Science Nord, Max-Planck-Innovation GmbH, Innovations- und Gründerzentrum (IGZ) Würzburg, Ascenion GmbH, BIO Deutschland e. V., Pieter De Maeght, Philipp Baaske, Garima Bhardwaj, Ph.D., Agnieszka G., Bartosz Kajdas